Potentia Pharmaceuticals aims to bring new classes of anti-inflammatory drugs to the market to address chronic inflammatory diseases in areas of significant unmet need such as age-related macular degeneration, atherosclerosis, uveitis, rheumatoid arthritis, multiple sclerosis, and Alzheimer's disease.

To support this vision, Potentia explores novel mechanisms to inhibit inflammation, such as inhibition of complement activation, and assembles an innovative and multi-faceted drug pipeline through a combination of selective in-licensing and internal research and development. As an important component of its long-term strategy, the Company also engages in and catalyses the development of broad-ranging and complementary technologies such as drug delivery systems and diagnostic tools through collaborations and grant-funded programs.